TG Therapeutics Inc [TGTX] stock is trading at $34.02, up 0.71%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TGTX shares have gain 1.58% over the last week, with a monthly amount drifted -6.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 29, 2024, TD Cowen initiated with a Buy rating and assigned a price target of $50 on the stock. Goldman upgraded its rating to a Neutral and decreased its price target to $12 on August 02, 2023. BofA Securities started tracking with a Underperform rating for this stock on May 20, 2022, and assigned it a price target of $5. In a note dated February 23, 2022, B. Riley Securities reiterated an Buy rating on this stock and revised its target price from $49 to $35.
TG Therapeutics Inc [TGTX] stock has fluctuated between $22.92 and $46.48 over the past year. Currently, Wall Street analysts expect the stock to reach $60 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $34.02 at the most recent close of the market. An investor can expect a potential return of 76.37% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
TG Therapeutics Inc [NASDAQ:TGTX] reported sales of 454.07M for the trailing twelve months, which represents a growth of 92.13%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.19%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.26 and Total Capital is 0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.49 points at the first support level, and at 32.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 34.67, and for the 2nd resistance point, it is at 35.32.
Ratios To Look Out For
For context, TG Therapeutics Inc’s Current Ratio is 3.86. Further, the Quick Ratio stands at 2.96, while the Cash Ratio is 0.75. Considering the valuation of this stock, the price to sales ratio is 11.89, the price to book ratio is 19.45 and price to earnings (TTM) ratio is 90.91.
Transactions by insiders
Recent insider trading involved Lonial Sagar, Director, that happened on Sep 11 ’25 when 20852.0 shares were sold. Director, Lonial Sagar completed a deal on Sep 11 ’25 to buy 20852.0 shares. Meanwhile, Director Echelard Yann sold 10000.0 shares on Jun 13 ’25.
